Myriad Genetics Appoints Ben Wheeler as CFO

By Hao Liu • Monday, August 18 10:14 • Permanent Link

Myriad Genetics, Inc. (NASDAQ: MYGN) has appointed Ben Wheeler as its new Chief Financial Officer, effective August 16, 2025. Wheeler, who has been with Myriad for more than 13 years, brings extensive knowledge of the business and a strong financial expertise to the role. He has held various leadership positions within the company, including Vice President, Corporate Controller and Senior Vice President, Accounting.

Scott Leffler, the previous Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the board of directors through September 2, 2025.

Myriad Genetics is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025.

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company that develops and offers molecular tests to assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties. Today the company's shares have moved -3.06% to a price of $5.71. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.